Stifel analyst Stephen Willey lowered the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $21 and keeps a Buy rating on the shares. The firm views the recent activation of the first Zevaskyn Qualified Treatment Center and the anticipated treatment of the first patient in August 2025 as “an encouraging development,” the analyst tells investors in a Q1 recap note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics price target raised to $27.50 from $25 at Alliance Global Partners
- Abeona Therapeutics reports Q1 EPS (24c), consensus (35c)
- Abeona Therapeutics sees cash runway through early 2026
- Abeona, Lurie Children’s opens first center for ZEVASKYN gene therapy
- Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives